2024 has seen significant advancements and approvals in the biosimilars and pharmaceutical sectors, including the launch of Wegovy® in Australia, new indications for Opdivo®, and approvals for biosimilars in Canada and Europe. Additionally, there have been notable developments in clinical trials and legal disputes over patents.

2024 has seen major advancements and approvals in the biosimilars and pharmaceutical sectors, including the launch of new treatments, regulatory approvals, and significant financial performances by leading companies.

Lasofoxifene demonstrated a strong tolerability profile and promising Ki67 suppression in a Phase 2 I-SPY 2 trial arm, supporting further exploration in the neoadjuvant setting.

The USAN Council has approved "pegrizeprument" as the nonproprietary name for Veloxis Pharmaceuticals' lead transplant candidate VEL-101, marking a significant milestone in the drug's development pathway.

NRx Pharmaceuticals is on track to file NDAs for NRX-100 (IV Ketamine) and NRX-101 (Oral D-Cycloserine/Lurasidone) by year-end 2024 for treating suicidal ideation and bipolar depression.

Glenmark Pharmaceuticals has agreed to pay $7 million to settle antitrust lawsuits with three major healthcare entities - Humana, Centene, and Kaiser - over generic cholesterol medications Zetia and Vytorin.

Vertex Pharmaceuticals Incorporated experienced a decline in stock value due to setbacks in clinical trials for its new therapeutic, suzetrigine, aimed at treating chronic pain. Despite this, the company remains optimistic about its future trials and continues to focus on its cystic fibrosis treatments and other pipeline assets.

Perspective Therapeutics' VMT-α-NET program shows promising early results in neuroendocrine tumors, with no dose-limiting toxicities observed in Phase 1/2a trials.

Lasofoxifene demonstrates a strong tolerability profile and promising Ki67 suppression in a Phase 2 study, supporting further exploration in the neoadjuvant setting.

Vanda Pharmaceuticals reported a 23% increase in Q3 2024 revenues, reaching $47.7 million, driven by sales of Fanapt, HETLIOZ, and PONVORY.

Elite Pharmaceuticals has launched its generic version of Percocet® (oxycodone hydrochloride and acetaminophen tablets) in three strengths, targeting a market with annual sales of approximately $317 million.

Cantex Pharmaceuticals' azeliragon has been granted FDA Orphan Drug Designation for treating brain metastasis from breast cancer, addressing a critical unmet need.

Algernon Pharmaceuticals has received a notice of allowance from the European Patent Office for Repirinast (NP-251) in chronic kidney disease treatment, with patent protection extending through 2038.

The Japan Patent Office has granted Conduit Pharmaceuticals a composition of matter patent for AZD1656, a Glucokinase Activator targeting autoimmune disorders including Lupus and ANCA Vasculitis.

Pfizer has acquired Amplyx Pharmaceuticals, gaining rights to fosmanogepix, a novel Phase 2 antifungal compound that could address drug-resistant fungal infections with mortality rates of 30-80%.

Amylyx Pharmaceuticals has appointed Dan Monahan as Chief Commercial Officer to lead the commercialization of their product portfolio.

Qualigen Therapeutics is offering 14.7 million shares of common stock at $0.13 per share to fund operations and cancer drug development.

CERO Therapeutics received FDA clearance for its IND application for CER-1236, a genetically engineered human immune cell therapy, on November 15, 2024.

Tenax Therapeutics is developing levosimendan for pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF), a condition affecting over 2 million U.S. patients.

Annovis Bio's Buntanetap is currently in Phase II/III clinical trials for treating mild to moderate Alzheimer's and early Parkinson's, showing potential cognitive benefits.